SCHEMBL21035522

SCHEMBL21035522

COC(=O)[C@@H]1C[C@H](Oc2ccccc2)CN1S(=O)(=O)c1ccc2cc(OC3CCCC3)ccc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 4/20 0.43
MMP3 P08254 4/20 0.43
MMP9 P14780 2/20 0.43
HCRTR1 O43613 1/20 0.43
HCRTR2 O43614 1/20 0.43
ADAM17 P78536 1/20 0.43
MMP7 P09237 3/20 0.42
KAT6A Q92794 1/20 0.41
MMP2 P08253 1/20 0.41
ANPEP P15144 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
CASP3 P42574 1/20 0.39
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
MME P08473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21034977 0.95 CA12 (0.46) MMP1MMP3MMP9HCRTR1HCRTR2
SCHEMBL21035352 0.95 CA12 (0.46) MMP1MMP3MMP9HCRTR1HCRTR2
SCHEMBL21035398 0.92 HTR1A (0.42) MMP1MMP3MMP9HCRTR1HCRTR2
SCHEMBL21035317 0.92 HTR1A (0.42) MMP1MMP3MMP9HCRTR1HCRTR2
SCHEMBL21035318 0.91 MMP1 (0.43) MMP1MMP3MMP9HCRTR1HCRTR2
SCHEMBL21035402 0.91 MMP1 (0.43) MMP1MMP3MMP9HCRTR1HCRTR2
SCHEMBL21035523 0.90 AKR1C3 (0.43) MMP1MMP3MMP9HCRTR1HCRTR2
SCHEMBL21036273 0.90 MMP9 (0.42) MMP1MMP3MMP9HCRTR1HCRTR2
SCHEMBL21035405 0.90 MMP9 (0.42) MMP1MMP3MMP9HCRTR1HCRTR2
SCHEMBL21034981 0.87 MMP1 (0.45) MMP1MMP3MMP9HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019104011-A1 CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE BIOMARIN PHARMACEUTICAL INC. (US) 2019-05-31 WO disclosed